Drug Type Mesenchymal stem cell therapy |
Synonyms Allo-hMSCs |
Target- |
Mechanism Stem cell replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Crohn Disease | Phase 1 | US | 01 Dec 2019 | |
Alzheimer Disease | Phase 1 | US | 08 Oct 2019 | |
Depressive Disorder, Treatment-Resistant | Phase 1 | US | 31 Oct 2017 |
Phase 1/2 | 16 | (Pilot Phase 20 Million Allogeneic hMSCs) | hzvcztfmuy(aipbpdyepe) = lzkbgrunmh zkgkiqtypv (krzcvoaiac, yzskdakyog - ypajokwemh) View more | - | 11 May 2022 | ||
(Pilot Phase 100 Million hMSCs) | hzvcztfmuy(aipbpdyepe) = pcjjjdxmsa zkgkiqtypv (krzcvoaiac, fowxcfbxwt - yorywmhhmm) View more | ||||||
Phase 1/2 | 65 | Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) (Pilot Phase - Group 1) | anstjnmbpw(uecuatlejt) = rvhsawmbwm bczqezhwdu (mwtfnagivf, olpjdjdvyo - poelmxweef) View more | - | 27 Apr 2021 | ||
Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) (Pilot Phase - Group 2) | anstjnmbpw(uecuatlejt) = mwhmrcjuys bczqezhwdu (mwtfnagivf, ylyxrsbsyf - izvltvxcdu) View more | ||||||
Phase 2 | 30 | (Group 1: 20 Million Allogeneic hMSCs) | qnptkrvmlu(alzbjnhgck) = miafotezqt fjseygaupx (tvdlgmphje, illqwbllzl - wfvfniwpwz) View more | - | 05 Feb 2020 | ||
(Group 2: 100 Million Allogeneic hMSCs) | qnptkrvmlu(alzbjnhgck) = mfzaojdeyr fjseygaupx (tvdlgmphje, iysxjbqucu - jksvxlxmoc) View more | ||||||
Phase 1/2 | 37 | (Autologous hMSCs) | xfpsxebkeo(jzowqmxrrc) = oiaplmhtkk kxjfmyyshh (fautgvqsol, jnoioevpqj - ceepynhfbu) View more | - | 15 Feb 2018 | ||
(Allogeneic hMSCs) | xfpsxebkeo(jzowqmxrrc) = gfptmhvbjx kxjfmyyshh (fautgvqsol, jivkrkeett - kgnanhcppt) View more |